Why Uterine Fibroids Remain a Major Unmet Medical Need

Uterine fibroids (uterine leiomyomata) are the most common benign tumors of the female reproductive tract, affecting up to 70–80% of women by age 50 and occurring in up to 20% of women over 30 years of age. Despite this prevalence, the pharmacological treatment landscape remains thin: as of 2025, leuprolide acetate — a GnRH agonist — is the only FDA-approved drug for shrinking uterine fibroids, and only as short-term preoperative treatment. This gap between disease burden and available therapy is the central driver of current patent activity.

The molecular rationale for pharmacological intervention centers on sex steroid hormone dependency. Estradiol is identified as a primary driver of fibroid growth, with high estradiol levels promoting tumor proliferation. The progesterone receptor (PR) pathway functions as a co-driver of fibroid growth and a tractable pharmacological target. Key clinical manifestations described across multiple patent filings include heavy menstrual bleeding (menorrhagia), dysmenorrhea, chronic pelvic pain, anemia, urinary frequency, and impaired fertility.

Beyond the dominant hormonal targets, secondary molecular nodes have attracted patent activity. The HMGA2 and MDM2/p19ARF axis is implicated in mesenchymal stem cell–derived leiomyoma growth, with filings from Universität Bremen describing diagnostic and therapeutic approaches targeting these oncoproteins. The MED12 mutation is identified as a subtype-defining genetic alteration in fibroids, with Yamaguchi University filing patents in 2023 and 2025 for MRI-based AI prediction tools to identify MED12-positive fibroid subtypes. Fibroblast growth factor receptors (FGFR/bFGF), collagen/extracellular matrix architecture, and pigment epithelium-derived factor (PEDF) round out the secondary target landscape.

Oral GnRH Antagonists: The Dominant Active Patent Cluster

Oral non-peptide GnRH antagonists constitute the most active and commercially advanced segment of the current uterine fibroids drug patent landscape, with three distinct compounds — linzagolix (ObsEva S.A.), elagolix (AbbVie Inc.), and relugolix (Takeda Pharmaceutical Company) — each supported by active or recently active patent families across major jurisdictions. All three operate by competitively and reversibly blocking the pituitary GnRH receptor, suppressing LH and FSH release, and thereby lowering circulating estradiol and progesterone to reduce fibroid volume and associated bleeding.

ObsEva S.A. represents the single most prolific assignee in this dataset, holding at least 7 patent records across WO, US, CA, AU, SG, and JP jurisdictions (2021–2022), all disclosing compositions and dosing strategies for the thieno[3,4d]pyrimidine-derived compound linzagolix (chemical name: 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4d]pyrimidine-5-carboxylic acid, choline salt). A distinguishing pharmacological claim is the ability to implement “add-back” hormonal therapy during or after GnRH antagonist treatment — a feature that distinguishes these antagonists from older GnRH agonists, which require a delay before hormonal add-back. The ObsEva filings also describe dosing schedules enabling “extended treatment periods of multiple years” and fertility recovery windows, language characteristic of Phase II/III clinical dosing protocol design.

“Oral GnRH antagonists allow immediate hormonal add-back therapy and treatment can be temporarily halted to allow recovery of fertility potential — attributes absent from GnRH agonist approaches.”

AbbVie Inc. holds three active US patents (2019–2023) for elagolix (4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid) in combination with estrogens (estradiol) and progestogens (norethindrone acetate) for treating heavy menstrual bleeding with or without uterine fibroids. The add-back combination strategy is explicitly central to AbbVie’s IP claims, and the patent family explicitly references published clinical data including the Cochrane Database review of GnRH analogue therapy (Lethaby et al., 2009), indicating advanced translational positioning. Takeda Pharmaceutical Company’s patent discloses relugolix (N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N’-methoxyurea) at 10–60 mg/day, with endpoints including reducing bone mineral density loss and maintaining blood glucose and lipid profiles — markers consistent with clinical trial safety monitoring.

The SPRM Landscape: Regulatory Headwinds and Expiring IP

Selective progesterone receptor modulators (SPRMs) represent the second most represented modality in this dataset, but the IP landscape is in a fundamentally different position from GnRH antagonists: most SPRM patent families are now inactive or expired, consistent with well-documented regulatory headwinds that have prevented FDA approval of any SPRM for uterine fibroids. The primary compound in this space, ulipristal acetate (UPA), was championed by Preglem SA (subsequently acquired by Gedeon Richter) and Laboratoire HRA-Pharma, with at least 8 patent records across WO, EP, CA, AU, US, MX, UY, and HK jurisdictions filed between 2014 and 2017.

The academic literature result from the MRC Centre for Reproductive Health, University of Edinburgh (2017) — the only non-patent source in this dataset specifically addressing fibroid treatment — provides mechanistic detail on why SPRMs have faced regulatory scrutiny. In an observational clinical study of UPA effects on endometrium in fibroid patients (n=9 hysterectomy samples), UPA administration altered expression of sex-steroid receptors and progesterone-regulated genes and was associated with low levels of glandular and stromal cell proliferation. These SPRM-associated endometrial changes (PAEC) were observed with all SPRM-class members and have directly influenced regulatory decisions, according to the European Medicines Agency. A hepatotoxicity signal further compounded the regulatory challenges for ulipristal acetate.

Bayer Pharma Aktiengesellschaft’s retrieved patents describe a distinct steroidal PR antagonist — (11β,17β)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one — across TR (2019) and BR (2018) jurisdictions, with claims covering uterine fibroids, endometriosis, heavy menstrual bleeding, and meningioma. Both Bayer filings are now inactive. Jenapharm GmbH & Co. KG discloses mesoprogestins — a distinct SPRM subclass with mixed PR agonist/antagonist activity in vivo — for treatment and prevention of uterine fibroids, endometriosis, and dysfunctional uterine bleeding.

One structurally differentiated approach that remains at IP stage involves intravaginal delivery of low-dose SPRMs or anti-progestins. Arstat Inc. (formerly Rubin, Arkady) discloses vaginal rings or intrauterine devices (IUDs) delivering daily doses in the 50 µg–1 mg range directly to fibroid tissue, aiming to achieve local uterine tissue concentrations with minimal systemic exposure. Although the retrieved filings are inactive, this route-of-administration strategy could be revisited with newer SPRM or anti-progestational chemical entities, according to the World Health Organization‘s framework for local drug delivery in gynecological conditions.

Non-Hormonal Approaches: Collagenase, Nutraceuticals, and Kinase Inhibitors

Non-hormonal approaches to uterine fibroids represent early-stage but strategically differentiated IP positions that avoid the hypoestrogenic side effect burden of hormone-targeted therapy, positioning them for patient populations contraindicated for hormonal treatment or seeking fertility preservation with minimized systemic effects. Three distinct non-hormonal modalities are represented in the retrieved patent dataset.

Collagenase Injection: Enzymatic Fibroid Dissolution

Biospecifics Technologies Corporation holds an active Canadian patent (2021) and an active European patent (2025) disclosing direct intra-fibroid injection of purified collagenase to cause shrinkage or elimination of fibroid tissue. This approach targets the aberrant extracellular matrix collagen architecture of uterine fibroids — described in Lo.Li. Pharma filings as disorganized and forming the rigid structural characteristic of leiomyomas. The 2025 EP active status signals ongoing IP prosecution and positions this as a potentially emerging non-surgical, non-hormonal approach. The Biospecifics EP filing explicitly acknowledges the unmet need context, noting that SPRMs have failed FDA approval and that leuprolide acetate remains the only FDA-approved medical therapy for fibroid shrinkage but only as short-term preoperative treatment, consistent with guidance from the FDA.

Vitamin D + EGCG: Anti-Fibrotic Nutraceutical Combination

Lo.Li. Pharma S.R.L. holds multiple active patents (IT, EP active; WO, CA, MX, PE) disclosing combinations of Vitamin D and catechin-class polyphenols — principally epigallocatechin gallate (EGCG) — for the prevention, control, and treatment of uterine fibroids. The EP patent granted in 2024 represents the most recent active IP in this cluster. The scientific rationale relates to collagen matrix abnormalities in fibroid tissue and the potential anti-proliferative and anti-fibrotic properties of these agents. No clinical trial data or efficacy endpoints are described in the retrieved filings; this modality appears to be at an early, potentially nutraceutical-adjacent development stage.

Multikinase Inhibitors for Reproductive Tract Fibrosis

Aiviva Biopharma, Inc. holds an active Canadian patent (2019) describing the use of multikinase inhibitors — axitinib, nintedanib, sunitinib, lenvatinib, regorafenib, ponatinib, pazopanib, and riociguat — for preventing and treating fibrosis associated with uterine fibroids and related reproductive tract conditions. The mechanistic rationale connects fibroid pathology to dysregulated fibrotic signaling cascades addressable by kinase inhibition. No efficacy data are described in the retrieved filing; this represents an emerging hypothesis that anti-fibrotic kinase inhibitors approved or in development for other fibrotic conditions may have utility in uterine fibroids, a direction also supported by research published by The New England Journal of Medicine on anti-fibrotic mechanisms in smooth muscle tissue.

Combination Strategies and Emerging Directions in the Fibroid Pipeline

Combination approaches and emerging therapeutic directions signal where the uterine fibroids pipeline is heading beyond single-agent hormone suppression. The retrieved patent dataset identifies six distinct combination or emerging strategies, ranging from well-protected clinical-stage combinations to early-stage diagnostic innovations.

The most consistently signaled combination strategy across the dataset is GnRH antagonist + hormonal add-back. Both ObsEva (linzagolix) and AbbVie (elagolix) patent families explicitly protect the combination of GnRH antagonist with estrogen (estradiol) and progestogen (norethindrone acetate) to mitigate hypoestrogenic side effects while maintaining fibroid-suppressing efficacy. The Takeda relugolix patent extends this to methods for preserving bone mineral density and lipid profiles. This add-back paradigm represents the dominant combination IP strategy in the retrieved dataset.

A second structurally novel combination strategy comes from Preglem SA: a method patent (MX active; IL inactive) describes co-administering one progesterone receptor modulator orally and a second via vaginal or intrauterine administration, targeting the same pathology through complementary routes — an attempt to achieve systemic fibroid control while delivering locally concentrated drug to pelvic tissue. Multiple Preglem SA filings also describe SPRM + progestin sequential therapy, with ulipristal acetate treatment courses followed by progestin administration to manage PAEC between treatment cycles, designed to enable longer-term SPRM use while maintaining endometrial safety.

An emerging diagnostic dimension is represented by Yamaguchi University’s 2023 and 2025 patent filings for MRI-based AI prediction tools to identify MED12 mutation-positive fibroid subtypes using fibrosis-sensitive imaging sequences. This signals a direction toward biomarker-informed patient stratification for fibroid treatment — potentially enabling companion diagnostic–drug co-development strategies analogous to oncology paradigms, a model well-established according to WIPO‘s analysis of precision medicine patent trends.

“The MED12 mutation subtype stratification signal from Yamaguchi University suggests that biomarker-informed patient selection may become increasingly important for fibroid drug development, potentially enabling companion diagnostic–drug co-development strategies similar to oncology paradigms.”

Strategic Implications for Drug Developers and IP Teams

The uterine fibroids patent landscape presents a clear two-tier structure: a well-defended, commercially advanced GnRH antagonist cluster and a largely exhausted SPRM landscape with emerging non-hormonal alternatives at various early stages. Understanding these dynamics is essential for freedom-to-operate analysis, competitive intelligence, and pipeline positioning.

GnRH antagonist add-back regimens constitute the dominant active IP cluster in this dataset. The convergence on thieno[3,4d]pyrimidine scaffolds across ObsEva, AbbVie, and Takeda signals a well-validated chemical space that may present freedom-to-operate challenges for new entrants. However, dosing regimen and combination composition claims may offer differentiation opportunities — particularly for novel add-back hormone combinations or extended-release formulations not currently claimed.

The SPRM patent landscape is largely exhausted, with most Preglem SA and HRA-Pharma filings now inactive or expired. The hepatotoxicity regulatory signal and absence of FDA approval create an opening for next-generation SPRMs with improved safety profiles, if the endometrial PAEC concern can be structurally addressed in new chemical entities. The intravaginal delivery approach (Arstat Inc./Rubin) presents a route-of-administration IP angle that may be revisitable with newer SPRM or anti-progestational chemical entities, despite the current inactive status of those filings.

Non-hormonal approaches — collagenase injection, multikinase inhibitors, and Vitamin D/EGCG combinations — represent early-stage but strategically differentiated IP positions. These modalities are positioned for patient populations contraindicated for hormonal treatment or seeking fertility preservation with minimized systemic effects. The Biospecifics EP active status (2025) and Lo.Li. Pharma EP grant (2024) suggest these positions are being actively maintained.

The MED12 mutation subtype stratification signal from Yamaguchi University suggests that biomarker-informed patient selection may become increasingly important for fibroid drug development. Connecting fibroid subtype to therapeutic choice could potentially enable personalized pharmacological approaches — a model that PatSnap’s life sciences intelligence platform is well-positioned to support through integrated patent and biomarker landscape analysis. The convergence of diagnostic and therapeutic IP in fibroid management mirrors trends in oncology and represents a strategic white space for co-development partnerships.